Proteon Therapeutics Inc (NASDAQ:PRTO) has been assigned an average recommendation of “Hold” from the six research firms that are covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, four have issued a hold recommendation and one has given a buy recommendation to the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $3.43.
Several analysts have weighed in on the stock. Zacks Investment Research upgraded shares of Proteon Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Thursday, January 4th. Robert W. Baird reiterated a “hold” rating and set a $2.00 target price on shares of Proteon Therapeutics in a research note on Friday, November 10th. Finally, HC Wainwright reiterated a “hold” rating and set a $2.30 target price on shares of Proteon Therapeutics in a research note on Wednesday, November 8th.
Proteon Therapeutics (NASDAQ:PRTO) traded up $0.05 on Tuesday, reaching $2.20. 12,580 shares of the company traded hands, compared to its average volume of 70,469. The firm has a market capitalization of $38.76, a PE ratio of -0.99 and a beta of 1.78. Proteon Therapeutics has a 1 year low of $1.10 and a 1 year high of $2.85.
In other Proteon Therapeutics news, Director James E. Flynn bought 110,557 shares of the stock in a transaction on Thursday, November 30th. The stock was purchased at an average price of $1.75 per share, for a total transaction of $193,474.75. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 36.30% of the stock is owned by insiders.
An institutional investor recently raised its position in Proteon Therapeutics stock. Renaissance Technologies LLC lifted its position in shares of Proteon Therapeutics Inc (NASDAQ:PRTO) by 17.2% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 201,500 shares of the biopharmaceutical company’s stock after acquiring an additional 29,600 shares during the period. Renaissance Technologies LLC owned 1.14% of Proteon Therapeutics worth $383,000 as of its most recent filing with the SEC. 49.99% of the stock is owned by institutional investors.
Proteon Therapeutics Company Profile
Proteon Therapeutics, Inc is a late-stage biopharmaceutical company, which focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. The Company is involved in research and development activities. The Company’s product candidate, product candidate, vonapanitase, formerly PRT-201, is a recombinant human elastase that it is developing to manage vascular access failure in patients with chronic kidney disease undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access.
Receive News & Ratings for Proteon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.